Back to discover
Drug

Vincristine

In clinical development
Emerging researchLate-stage development
Also known as 22-Oxovincaleukoblastin, 22-Oxovincaleukoblastine, LCR, Leurocristine+7 more

22-Oxovincaleukoblastin, 22-Oxovincaleukoblastine, LCR, Leurocristine, Marqibo, VCR, Vincasar, Vincristin, Vincristina, VinCRIStine Sulfate, Vincristinum.

RxNorm11202ChEMBLCHEMBL499458UNII5J49Q6B70F
2
Research papers
51
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Clinical trial2026-07-24Results expected Q4 2030 · ClinicalTrials.gov

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Clinical trial2026-07-16Results expected Q1 2028 · ClinicalTrials.gov

A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Clinical trial2026-07-16Results expected Q4 2027 · ClinicalTrials.gov

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Clinical trial2026-07-16Results expected Q3 2029 · ClinicalTrials.gov

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma

Clinical trial2026-07-15Results expected Q4 2026 · ClinicalTrials.gov

A Randomized Phase II Study Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Plus Blinatumomab Compared to Usual Chemotherapy Plus Blinatumomab for Older Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Clinical trial2026-07-10Results expected Q2 2027 · ClinicalTrials.gov

A Phase Ib/II Study Evaluating the Safety and Efficacy of DA EPOCH in Combination With Mosuntuzumab (EPICSUN) in Previously Untreated C-Myc Rearrangement Positive High-Grade B Cell Lymphomas Including Myc Rearranged Diffuse Large B Cell Lymphoma and High Grade B Cell Lymphoma

Clinical trial2026-07-07Results expected Q4 2026 · ClinicalTrials.gov

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Clinical trial2026-07-06Results expected Q4 2030 · ClinicalTrials.gov

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Research2021-12-14The New England journal of medicine

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Research2014-03-03Blood

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vincristine
Aliases & brands
22-Oxovincaleukoblastin22-OxovincaleukoblastineLCRLeurocristineMarqiboVCRVincasarVincristinVincristinaVinCRIStine SulfateVincristinum
RxNorm CUI
11202
ChEMBL ID
CHEMBL499458
UNII
5J49Q6B70F

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
195
registered trials across all phases
LATEST COMPLETION 2026
51
Active studies
26
Recruiting
70
Late-stage (III+)
100
Completed
44
Discontinued
PHASE DISTRIBUTIONn = 195
Early Phase 12Phase 121Phase 1 / 222Phase 280Phase 2 / 31Phase 357Phase 47Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial

CompletedPH IVInstitute of Hematology & Blood Diseases Hospital, Chinan=552020

Ma-Spore ALL 2010 Study

Unknown statusPH IVNational University Hospital, Singaporen=5002018

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

CompletedPH IVAssiut Universityn=402018

German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)

CompletedPH IVJohann Wolfgang Goethe University Hospitaln=602009

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

CompletedPH IVPETHEMA Foundationn=3742007

Recent completions

Trials that read out recently, adding to the completed evidence base.

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

CompletedPH IIINational Cancer Institute (NCI)n=2362026

Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

CompletedPH IIIChildren's Oncology Groupn=8082026

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years

CompletedPH IIIChildren's Oncology Groupn=4792026

A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. the Same Therapy Without Methotrexate

CompletedPH IIIChildren's Oncology Groupn=912025

A Single-arm, Multi-center, Phase II Clinical Trial of R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Medium to High Risk/High Risk Diffuse Large B Cell Lymphoma

CompletedPH IIHenan Cancer Hospitaln=602025

Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

CompletedPH I/IIUniversity of Chicagon=552024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20142022
Journals, researchers & institutions
Top journals
  • Blood1
  • The New England journal of medicine1
Leading researchers
  • Burke JM2
  • Abrisqueta P1
  • Bergua-Burgués JM1
  • Chauchet A1
  • Chen L1
  • Cheung MC1
  • Clementi R1
  • Craig M1
Leading institutions
free-text, unnormalised
  • Centre Henri-Becquerel and University of Rouen1
  • Sarah Cannon Research Institute/Tennessee Oncology1

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cyclophosphamide

Studied across 9 of the same disease areas as Vincristine in the shared literature.

9 shared diseases2 shared papers
Doxorubicin

Studied across 9 of the same disease areas as Vincristine in the shared literature.

9 shared diseases2 shared papers
Prednisone

Studied across 9 of the same disease areas as Vincristine in the shared literature.

9 shared diseases2 shared papers
Bendamustine Hydrochloride

Studied across 8 of the same disease areas as Vincristine in the shared literature.

8 shared diseases1 shared paper
Polatuzumab vedotin

Studied across the same disease area as Vincristine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials